Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Infergen Market Expansion Outlook: What Revenue Opportunities Are Ahead?
Historical expansion during that era was driven by a significant worldwide incidence of hepatitis C, an early reliance on interferon treatments, the absence of alternative antiviral medications, antiviral treatment administered in hospital settings, and healthcare professionals’ familiarity with interferons.
The anticipated growth during the forecast period is attributable to a transition towards direct-acting antivirals, a specific demand in resistant instances, improvements in hepatitis screening initiatives, a sharpened focus on liver disease management, and a diminishing reliance on interferon. Concurrently, significant trends for this period involve a decrease in the use of interferon-based therapies, their selective application in patients resistant to treatment, the optimization of combination therapies, an emphasis on suppressing viral loads, and continuous monitoring of long-term liver outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Infergen Market Development Factors: What’s Supporting Demand?
The increasing occurrence of chronic hepatitis C is anticipated to fuel the expansion of the infergen market in the future. This enduring infection, caused by the hepatitis C virus, involves the virus remaining in the body for over six months, potentially resulting in severe health issues like liver damage, cirrhosis, and liver cancer if not addressed. The surge in chronic hepatitis C cases is primarily linked to higher rates of injection drug use, promoting blood-to-blood viral spread, alongside insufficient availability of preventive and therapeutic care. Infergen, a pegylated interferon alfa-2b formulation, aids those with chronic hepatitis C by activating the immune system to combat the virus, thus enhancing liver function, lowering viral load, and potentially achieving a sustained virologic response (SVR), vital for averting liver damage and disease-related complications. For example, in April 2025, data from the European Centre for Disease Prevention and Control (ECDC), a Europe-based body focused on enhancing defenses against infectious diseases, indicated that in 2023, 28622 cases of hepatitis C were documented across 29 EU/EEA countries, equating to a raw rate of 7.4 cases per 100 000 populations. Additionally, the reported cases showed 4.9% were acute, 34.1% chronic, and 53.8% were unknown. Consequently, the increasing incidence of chronic hepatitis C is propelling the expansion of the infergen market. The growing call for personalized medicine is projected to substantially boost the infergen market’s expansion. This approach entails tailoring healthcare interventions to suit each patient’s distinct attributes, requirements, and choices, frequently guided by their genetic profile, with the goal of improving treatment efficacy and reducing side effects by accounting for individual differences in genetics, surroundings, and way of life. Patients’ desire for more effective healthcare solutions, customized to their specific genetic, physiological, and lifestyle elements, is fueling the increasing demand for personalized medicine. Infergen (interferon alfacon-1) serves as a personalized medicine by adjusting treatment plans for chronic hepatitis C patients based on their unique factors, including viral load and genotype. For instance, in February 2024, the Personalized Medicine Coalition, a US-based group representing scientists, patients, and providers, reported that the U.S. Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. Consequently, the increasing need for personalized medicine is anticipated to propel the infergen market forward.
Infergen Market Segments: Where Is Growth Concentrated?
The infergen market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients, High-Risk Groups
2) By Application: Chronic Hepatitis C Treatment, Combination Therapy
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Pharmacies
Infergen Market Key Participants And Competitive Landscape
Major companies operating in the infergen market are Amgen Inc.
View The Full Infergen Market Report:
Infergen Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the infergen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infergen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
